Protagonist Therapeutics (PTGX) Short Interest Ratio & Short Volume → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free PTGX Stock Alerts $31.47 +1.86 (+6.28%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Protagonist Therapeutics Short Interest DataCurrent Short Volume3,730,000 sharesPrevious Short Volume3,520,000 sharesChange Vs. Previous Month+5.97%Dollar Volume Sold Short$93.66 millionShort Interest Ratio / Days to Cover6.6Last Record DateApril 30, 2024Outstanding Shares58,650,000 sharesPercentage of Shares Shorted6.36%Today's Trading Volume676,115 sharesAverage Trading Volume671,376 sharesToday's Volume Vs. Average101% Short Selling Protagonist Therapeutics ? Sign up to receive the latest short interest report for Protagonist Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatPTGX Short Interest Over TimePTGX Days to Cover Over TimePTGX Percentage of Float Shorted Over Time Ad Manward PressAmazon's betting big on this unknown AI companyAmazon's Betting Big on This Unknown AI Company Amazon has just made a stunning $144 million investment in one small AI company.Discover why this company Protagonist Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20243,730,000 shares $93.66 million +6.0%N/A6.6 $25.11 4/15/20243,520,000 shares $93.56 million +2.3%N/A5.2 $26.58 3/31/20243,440,000 shares $99.52 million +0.6%N/A4.6 $28.93 3/15/20243,420,000 shares $99.11 million +16.3%N/A4.7 $28.98 2/29/20242,940,000 shares $89.32 million +5.8%N/A3.6 $30.38 2/15/20242,780,000 shares $78.48 million +6.5%N/A3.5 $28.23 Get the Latest News and Ratings for PTGX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20242,610,000 shares $65.28 million +2.4%N/A3.2 $25.01 1/15/20242,550,000 shares $66.05 million +8.5%N/A3.5 $25.90 12/31/20232,350,000 shares $53.89 million -41.0%N/A3.3 $22.93 12/15/20233,980,000 shares $83.86 million +9.3%N/A5.6 $21.07 11/30/20233,640,000 shares $66.28 million -0.3%N/A5.4 $18.21 11/15/20233,650,000 shares $59.46 million -7.4%N/A5.7 $16.29 10/31/20233,940,000 shares $57.29 million +15.5%N/A6 $14.54 10/15/20233,410,000 shares $52.65 million +8.3%N/A5.3 $15.44 9/30/20233,150,000 shares $52.54 million +12.5%N/A4.5 $16.68 9/15/20232,800,000 shares $50.12 million +1.8%N/A3 $17.90 8/31/20232,750,000 shares $54.51 million -9.2%N/A2.8 $19.82 8/15/20233,030,000 shares $56.84 million +2.0%N/A2.8 $18.76 7/31/20232,970,000 shares $57.62 million -10.5%N/A2.7 $19.40 7/15/20233,320,000 shares $70.55 million +4.4%N/A2.8 $21.25 6/30/20233,180,000 shares $87.83 million +18.2%N/A2.7 $27.62 6/15/20232,690,000 shares $77.15 million -12.1%N/A2.5 $28.68 5/31/20233,060,000 shares $79.77 million -15.0%N/A2.5 $26.07 5/15/20233,600,000 shares $93.49 million -3.2%N/A2.2 $25.97 4/30/20233,720,000 shares $84.07 million -14.7%N/A2.2 $22.60 4/15/20234,360,000 shares $81.71 million +0.5%N/A2.5 $18.74 3/31/20234,340,000 shares $99.82 million -16.1%N/A2.6 $23.00 3/15/20235,170,000 shares $124.34 million +88.7%N/A3.2 $24.05 2/28/20232,740,000 shares $44.44 million +5.4%6.3%1.9 $16.22 2/15/20232,600,000 shares $42.43 million +2.0%6.0%2.5 $16.32 1/31/20232,550,000 shares $33.89 million +25.6%5.9%2.7 $13.29 1/15/20232,030,000 shares $24.71 million +14.0%4.7%2.4 $12.17 12/30/20221,780,000 shares $19.42 million -4.3%4.1%2.3 $10.91 12/15/20221,860,000 shares $17.73 million +6.9%4.3%2.4 $9.53 11/30/20221,740,000 shares $13.76 million -4.4%4.0%2.2 $7.91 11/15/20221,820,000 shares $14.63 million -7.6%4.2%2.4 $8.04 10/31/20221,970,000 shares $15.96 million -11.7%4.5%2.5 $8.10 10/15/20222,230,000 shares $17.82 million -8.2%5.1%2.6 $7.99 9/30/20222,430,000 shares $20.48 million -13.5%5.6%2.7 $8.43 9/15/20222,810,000 shares $23.24 million +9.3%6.5%2.8 $8.27This unknown company solves the biggest issue with AI (Ad)Nvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company PTGX Short Interest - Frequently Asked Questions What is Protagonist Therapeutics' current short interest? Short interest is the volume of Protagonist Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 3,730,000 shares of PTGX short. Learn More on Protagonist Therapeutics' current short interest. What is a good short interest ratio for Protagonist Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTGX shares currently have a short interest ratio of 7.0. Learn More on Protagonist Therapeutics's short interest ratio. Which institutional investors are shorting Protagonist Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Protagonist Therapeutics: PEAK6 Investments LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Protagonist Therapeutics' short interest increasing or decreasing? Protagonist Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 3,730,000 shares, an increase of 6.0% from the previous total of 3,520,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Protagonist Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Protagonist Therapeutics: Morphic Holding, Inc. (12.82%), Akero Therapeutics, Inc. (12.44%), Xencor, Inc. (10.83%), Day One Biopharmaceuticals, Inc. (18.47%), Dynavax Technologies Co. (14.99%), Kiniksa Pharmaceuticals, Ltd. (5.51%), Taro Pharmaceutical Industries Ltd. (0.68%), Kura Oncology, Inc. (13.59%), Arcus Biosciences, Inc. (16.36%), ANI Pharmaceuticals, Inc. (1.09%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Protagonist Therapeutics stock? Short selling PTGX is an investing strategy that aims to generate trading profit from Protagonist Therapeutics as its price is falling. PTGX shares are trading up $1.86 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Protagonist Therapeutics? A short squeeze for Protagonist Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of PTGX, which in turn drives the price of the stock up even further. How often is Protagonist Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTGX, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Morphic Short Interest Akero Therapeutics Short Interest Xencor Short Interest Day One Biopharmaceuticals Short Interest Dynavax Technologies Short Interest Kiniksa Pharmaceuticals Short Interest Taro Pharmaceutical Industries Short Interest Kura Oncology Short Interest Arcus Biosciences Short Interest ANI Pharmaceuticals Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTGX) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAmazon's betting big on this unknown AI companyManward PressWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingProtect Your Bank Account Before It’s Too LateWeiss RatingsGold Set to EXPLODE!Gold Safe Exchange"The Biggest Drug Ever" Is ComingBehind the MarketsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders